Thursday, August 7, 2025
StockstToday.com Logo
  • Home
  • Breaking News
  • Business & Industry Trends
  • Market News
  • Analyst Ratings
No Result
View All Result
  • Home
  • Breaking News
  • Business & Industry Trends
  • Market News
  • Analyst Ratings
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Ratings and Price Targets Indicate Bullish Outlook for Axsome Therapeutics

Elaine Mendonca by Elaine Mendonca
January 16, 2024
in Breaking News
0
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

As of January 16, 2024, the outlook for Axsome Therapeutics (NASDAQ:AXSM) appears to be largely positive based on recent analyst ratings and price targets. Over the past three months, the average price target for AXSM has been $119.29, with a high estimate of $180.00 and a low estimate of $108.00. This average target of $135.67 represents a substantial increase of 50.74% from the previous average price target of $90.00.

In the current month, AXSM has received 25 Buy Ratings, 1 Hold Rating, and 0 Sell Ratings from analysts. Notably, key analysts have taken actions such as raising price targets and maintaining buy ratings, which reflects their confidence in the company’s performance.

Here is a summary of the recent analyst ratings and price targets:

– David Amsellem from Piper Sandler has raised the rating to Overweight with a current price target of $113.00, up from the prior target of $90.00.
– Raghuram Selvaraju from HC Wainwright & Co. has maintained a Buy rating with a price target of $180.00.
– Charles Duncan from Cantor Fitzgerald has maintained an Overweight rating with a price target of $108.00.
– David Hoang from Citigroup has announced a Buy rating with a price target of $125.00.

The majority of analysts have given buy or overweight ratings, and their price targets are significantly higher than the current price. This indicates a positive sentiment towards the future performance of Axsome Therapeutics.

In conclusion, the analyst landscape for Axsome Therapeutics suggests a bullish outlook. The majority of analysts maintain buy ratings and have significantly increased their price targets, demonstrating confidence in the company’s future prospects.

AXSM Stock: Strong Performance and Positive Momentum in After-Hours Trading – January 16, 2024

On January 16, 2024, AXSM stock displayed a strong performance, trading near the top of its 52-week range and above its 200-day simple moving average. The price of AXSM shares experienced a slight decrease of $0.26 since the market closed, representing a drop of 0.31%. However, in after-hours trading, AXSM stock showed a positive momentum by rising $0.28. Investors may find AXSM stock appealing due to its strong performance relative to its 52-week range and the fact that it is trading above its 200-day simple moving average. It is important to note that stock prices can be influenced by various factors, including market conditions, company news, and economic trends. Therefore, it is crucial for investors to conduct thorough research and analysis before making any investment decisions.

AXSM Stock Performance: Mixed Results on January 16, 2024 – Importance of Monitoring Financial Reports and Market Factors

On January 16, 2024, AXSM stock experienced a mixed performance, with some positive and negative indicators. The net income for the company was reported to be -$187.13 million in the previous year, representing a 43.5% decrease compared to the previous year. However, there has been a slight improvement in the net income since the last quarter, with a reported figure of -$62.20 million, indicating a 7.4% increase. Similarly, the EPS for the previous year stood at -$4.60, showing a decrease of 32.79% compared to the previous year. However, there has been a positive change in EPS since the last quarter, with a reported figure of -$1.32, indicating a 14.17% increase. While the decrease in net income and EPS over the past year may raise concerns for investors, the recent improvements in these figures since the last quarter could be seen as a positive sign. However, it is important to note that without the total revenue data, it is challenging to gauge the overall financial performance of AXSM accurately. Investors and analysts should closely monitor AXSM’s financial reports, including the total revenue figures, to gain a more accurate understanding of the company’s financial health. It is also advisable to consider other factors such as market trends, industry performance, and any significant developments or announcements from AXSM that may impact its stock performance. In conclusion, AXSM’s stock performance on January 16, 2024, showcased a mixed bag of results. Investors should exercise caution and closely monitor AXSM’s financial reports and other market factors to make informed investment decisions.

Tags: AXSM
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
SO stock news

Goldman Sachs CEO Optimistic for Positive Shift in Credit Card Partnerships

Technology Robotics Markets and money

Analyst Shows Confidence in Adtran with Buy Rating and Solid Price Target

Telecommunications Industry stock Trading

EchoStar Receives Coverage Initiation Following Successful Merger A Dominant Global Connectivity Leader Emerges

Recommended

ALB stock news

Allspring Global Investments Increases Stake in Automotive Parts Company, Douglas Dynamics Inc.

2 years ago
Technology Robotics Markets and money

Exela Technologies Inc and XBP Europe Launch Reaktrai Revolutionizing Cybersecurity and Data Management with AI

2 years ago

Positive Outlook and Increased Price Target for Corteva

2 years ago
Alternative Energy Markets and money (1)

Ecopetrols Commitment to Thorough Evaluation and Reliable Results for Arauca 8 Well

2 years ago

Categories

  • Analyst Ratings
  • Breaking News
  • Business & Industry Trends
  • Market News
  • Stock Picks
  • Stock Targets
  • Stocks
  • Uncategorized

Topics

AAL AAPL ABNB ADBE ADSK ALB AMD AMZN AVGO BA C CCL CELH COIN COST CRWD CTVA DELL DFS DIS DLR DLTR DWAC GM GRFS IBM INTC JPM KSS LLY META MSFT NFLX NVDA NVO ORCL PARA PLTR PLUG QCOM SMCI TGT TSLA UNH VZ
No Result
View All Result

Highlights

Lucid Group Stock: Turbulence Amid Policy Shifts and Uber Deal

Walt Disney Stock: Marvel Woes Offset by NFL Deal

Fresenius Stock: Mixed Q2 Results Amid Margin Pressures

Beiersdorf Stock: Nivea’s Glow Fades as Forecasts Dim

ABN Amro Stock: Profit Dip Amid Strong Capital Moves

Vonovia Stock: Strong Recovery Fuels Optimism

Trending

Snap Stock
Stocks

Snap Stock: Turmoil Amid Advertising Woes

by Dieter Jaworski
August 6, 2025
0

Snap Inc.'s stock has become a battleground for Wall Street analysts following disappointing Q2 results, with price...

DHL Stock

DHL Stock: Rollercoaster Ride Amid Strong Earnings

August 6, 2025
Klöckner Stock

Klöckner Stock: Turnaround Amid Market Volatility

August 6, 2025
Lucid Group Stock

Lucid Group Stock: Turbulence Amid Policy Shifts and Uber Deal

August 6, 2025
Walt Disney Stock

Walt Disney Stock: Marvel Woes Offset by NFL Deal

August 6, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Recent News

  • Siemens Stock: Mixed Q3 Results Amid Growth Challenges August 7, 2025
  • Duolingo Registered (A) Stock: Soars on Stellar Earnings August 7, 2025
  • Bayer Stock: Mixed Signals Spark Investor Turmoil August 7, 2025

Categories

  • Analyst Ratings
  • Breaking News
  • Business & Industry Trends
  • Market News
  • Stock Picks
  • Stock Targets
  • Stocks
  • Uncategorized

© 2024 Stocks Today

No Result
View All Result
  • Home
  • Breaking News
  • Business & Industry Trends
  • Market News
  • Analyst Ratings

© 2023 StocksToday.com